Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2011 3
2012 2
2014 2
2015 1
2016 1
2019 2
2023 1
2025 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
The following term was not found in PubMed: /
Page 1
Indirect Comparison of Ropinirole and Pramipexole as Levodopa Adjunctive Therapy in Advanced Parkinson's Disease: A Systematic Review and Network Meta-Analysis.
Zhao H, Ning Y, Cooper J, Refoios Camejo R, Ni X, Yi B, Parks D. Zhao H, et al. Adv Ther. 2019 Jun;36(6):1252-1265. doi: 10.1007/s12325-019-00938-1. Epub 2019 Apr 8. Adv Ther. 2019. PMID: 30963514
RESULTS: The indirect efficacy comparison resulted in a statistically nonsignificant off-time reduction difference (hours) of ropinirole-sustained release (SR) versus pramipexole-immediate release (MD - 0.25; 95% CI - 0.71, 0.21) and ropinirole-SR versus pramipexole …
RESULTS: The indirect efficacy comparison resulted in a statistically nonsignificant off-time reduction difference (hours) of ropinirole …
Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease.
Pahwa R, Stacy MA, Factor SA, Lyons KE, Stocchi F, Hersh BP, Elmer LW, Truong DD, Earl NL; EASE-PD Adjunct Study Investigators. Pahwa R, et al. Neurology. 2007 Apr 3;68(14):1108-15. doi: 10.1212/01.wnl.0000258660.74391.c1. Neurology. 2007. PMID: 17404192 Clinical Trial.
OBJECTIVE: To evaluate the efficacy of ropinirole 24-hour prolonged release (ropinirole 24-hour) as an adjunct to levodopa in patients with Parkinson disease (PD) and motor fluctuations. ...RESULTS: At week 24, the mean dose of ropinirole 24-hour was 18.8 mg/ …
OBJECTIVE: To evaluate the efficacy of ropinirole 24-hour prolonged release (ropinirole 24-hour) as an adjunct to levodopa in …
Drug safety evaluation of rotigotine.
Sprenger FS, Seppi K, Poewe W. Sprenger FS, et al. Expert Opin Drug Saf. 2012 May;11(3):503-12. doi: 10.1517/14740338.2012.678830. Epub 2012 Apr 3. Expert Opin Drug Saf. 2012. PMID: 22468676 Review.
Overall, these trials have shown that rotigotine has a similar adverse event (AE) profile as other non-ergolinic dopamine agonists such as pramipexole or ropinirole, inducing typical dopaminergic effects like nausea, daytime somnolence, peripheral edema or impulse c …
Overall, these trials have shown that rotigotine has a similar adverse event (AE) profile as other non-ergolinic dopamine agonists su …
Indirect comparisons of adverse events and dropout rates in early Parkinson's disease trials of pramipexole, ropinirole, and rasagiline.
Zagmutt FJ, Tarrants ML. Zagmutt FJ, et al. Int J Neurosci. 2012 Jul;122(7):345-53. doi: 10.3109/00207454.2012.660586. Epub 2012 Mar 23. Int J Neurosci. 2012. PMID: 22304415 Review.
The objective of this study was to perform an indirect comparison of Adverse Events (AEs) and Dropout Rates (DRs) among clinical trials of pramipexole, ropinirole, and rasagiline. Outcomes analyzed included DRs, total AEs, and AE categories: Cognitive (CG), Gastroin …
The objective of this study was to perform an indirect comparison of Adverse Events (AEs) and Dropout Rates (DRs) among clinical trials of p …
Therapeutic potential of lipid nanosystems for the treatment of Parkinson's disease.
Preetam S, Jonnalagadda S, Kumar L, Rath R, Chattopadhyay S, Alghamdi BS, Abuzenadah AM, Jha NK, Gautam A, Malik S, Ashraf GM. Preetam S, et al. Ageing Res Rev. 2023 Aug;89:101965. doi: 10.1016/j.arr.2023.101965. Epub 2023 May 31. Ageing Res Rev. 2023. PMID: 37268112 Review.
In this review, we will discuss the application and clinical significance of lipid nanosystem in delivering therapeutic compounds for anti-PD treatment. These medicinal compounds include ropinirole, apomorphine, bromocriptine, astaxanthin, resveratrol, dopamine, glyceryl m …
In this review, we will discuss the application and clinical significance of lipid nanosystem in delivering therapeutic compounds for anti-P …
Long-term, open-label, safety study of once-daily ropinirole extended/prolonged release in early and advanced Parkinson's disease.
Makumi CW, Asgharian A, Ellis J, Shaikh S, Jimenez T, VanMeter S. Makumi CW, et al. Int J Neurosci. 2016;126(1):30-8. doi: 10.3109/00207454.2014.991924. Epub 2014 Dec 27. Int J Neurosci. 2016. PMID: 25495896 Clinical Trial.
Long-term safety of once-daily ropinirole extended/prolonged release (ropinirole XL/PR) was evaluated in subjects with early and advanced Parkinson's disease (PD) in this study, 101468/248. ...Twenty-five percent of subjects discontinued the study prematurely due to …
Long-term safety of once-daily ropinirole extended/prolonged release (ropinirole XL/PR) was evaluated in subjects with early a …
Comparative safety signals of dopamine agonists: psychiatric and cardiovascular risks derived from FDA adverse event reporting system (FAERS) data.
Mu L, Xu J, Ye X, Jiang Y, Yi Z. Mu L, et al. BMC Pharmacol Toxicol. 2025 Mar 10;26(1):54. doi: 10.1186/s40360-025-00886-3. BMC Pharmacol Toxicol. 2025. PMID: 40065414 Free PMC article.
This study aims to compare adverse event (AE) data across various DAs to inform personalized treatment strategies. METHODS: AE reports with DAs as the "primary suspicion (PS)" were extracted from the FDA Adverse Event Reporting System (FAERS) database, covering 67 q …
This study aims to compare adverse event (AE) data across various DAs to inform personalized treatment strategies. METHODS: AE …
Ropinirole hydrochloride remedy for amyotrophic lateral sclerosis - Protocol for a randomized, double-blind, placebo-controlled, single-center, and open-label continuation phase I/IIa clinical trial (ROPALS trial).
Morimoto S, Takahashi S, Fukushima K, Saya H, Suzuki N, Aoki M, Okano H, Nakahara J. Morimoto S, et al. Regen Ther. 2019 Jul 26;11:143-166. doi: 10.1016/j.reth.2019.07.002. eCollection 2019 Dec. Regen Ther. 2019. PMID: 31384636 Free PMC article.
Thus, we developed a method of producing human spinal motor neurons using human induced pluripotent stem cells (iPSCs) and an innovative experimental technique for drug screening. As a result, ropinirole hydrochloride was eventually discovered after considering such result …
Thus, we developed a method of producing human spinal motor neurons using human induced pluripotent stem cells (iPSCs) and an innovative exp …
Long-term, open-label study of once-daily ropinirole prolonged release in early Parkinson's disease.
Hauser RA, Reichmann H, Lew M, Asgharian A, Makumi C, Shulman KJ. Hauser RA, et al. Int J Neurosci. 2011 May;121(5):246-53. doi: 10.3109/00207454.2010.546538. Epub 2011 Jan 19. Int J Neurosci. 2011. PMID: 21244307 Clinical Trial.
Long-term safety and efficacy of once-daily ropinirole prolonged release (PR) were evaluated in subjects with early Parkinson's disease (PD). ...These results support the extended use of ropinirole PR for treatment of PD....
Long-term safety and efficacy of once-daily ropinirole prolonged release (PR) were evaluated in subjects with early Parkinson's disea …
Overnight switch from ropinirole to transdermal rotigotine patch in patients with Parkinson disease.
Kim HJ, Jeon BS, Lee WY, Lee MC, Kim JW, Kim JM, Ahn TB, Cho J, Chung SJ, Grieger F, Whitesides J, Boroojerdi B. Kim HJ, et al. BMC Neurol. 2011 Aug 10;11:100. doi: 10.1186/1471-2377-11-100. BMC Neurol. 2011. PMID: 21831297 Free PMC article. Clinical Trial.
Switching treatment from oral ropinirole to transdermal rotigotine was carried out overnight, with a dosage ratio of 1.5:1. ...CONCLUSIONS: Switching treatment overnight from oral ropinirole to transdermal rotigotine patch, using a dosage ratio of 1.5:1, was well to …
Switching treatment from oral ropinirole to transdermal rotigotine was carried out overnight, with a dosage ratio of 1.5:1. ...CONCLU …
13 results